Odyssey Therapeutics, Inc. (ODTX)
| Market Cap | 1.12B |
| Revenue (ttm) | 99,000 -96.7% |
| Net Income | -160.03M |
| EPS | -14.05 |
| Shares Out | 47.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 555,204 |
| Open | 23.36 |
| Previous Close | 23.06 |
| Day's Range | 22.70 - 24.33 |
| 52-Week Range | 15.10 - 29.05 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 35.75 (+53.17%) |
| Earnings Date | Aug 4, 2026 |
About ODTX
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis... [Read more]
Financial Performance
In 2025, Odyssey Therapeutics's revenue was $2.98 million, a decrease of -33.45% compared to the previous year's $4.47 million. Losses were -$148.65 million, 14.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ODTX stock is "Strong Buy." The 12-month stock price target is $35.75, which is an increase of 53.17% from the latest price.
News
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care ...
Odyssey Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted an innovation-driven pipeline targeting upstream immune pathways for durable remissions in inflammatory and autoimmune diseases. OD-001 showed promising phase IIa results in IBD, with rapid efficacy even in refractory patients. Multiple clinical readouts are expected by 2027, with a focus on rapid development and commercialization.
H.C. Wainwright has increased confidence in Odyssey after Beeline data
H.C. Wainwright says Beeline Medicines’ Phase 2 success of afimetoran in systemic lupus erythematosus increases the firm’s confidence in Odyssey Therapeutics (ODTX)’ OD-002. The Beeline trial success ...
Odyssey Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar initiated coverage of Odyssey Therapeutics (ODTX) with a Buy rating and $44 price target The company is developing precision small molecules and protein therapeuti...
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care f...
Evotec enters R&D collaboration with Odyssey Therapeutics
Evotec (EVO) announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics (ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreem...
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Ody...
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b...
Odyssey Therapeutics Earnings release: Q2 2026
Odyssey Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Odyssey Therapeutics Quarterly report: Q2 2026
Odyssey Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Odyssey Therapeutics Slides: Corporate presentation
Odyssey Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on han...
Odyssey Therapeutics Quarterly report: Q1 2026
Odyssey Therapeutics has published its Q1 2026 quarterly earnings report on June 17, 2026.
Odyssey Therapeutics Earnings release: Q1 2026
Odyssey Therapeutics released its Q1 2026 earnings on June 17, 2026, summarizing the period's financial results.
Wedbush bullish on Odyssey Therapeutics, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $30 price target Odyssey’s lead candidate OD-001 is an oral RIPK2 scaffolding inhibitor ...
Wedbush bullish on Odyssey Therapeutics, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $30 price target Odyssey’s lead candidate OD-001 is an oral RIPK2 scaffolding inhibitor ...
Odyssey Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $30 price target
Odyssey Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jeff Jones initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $40 price target The company’s lead candidate, OD-001, has demonstrated clinical proof-of...
Odyssey Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Odyssey Therapeutics (ODTX) with an Overweight rating.
Odyssey Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Odyssey Therapeutics (ODTX) with a Buy rating and no price target Odyssey is pursuing novel biology for large immunology and inflammation markets, the analyst tells…
Odyssey Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Brian Cheng initiated coverage of Odyssey Therapeutics (ODTX) with an Overweight rating and $26 price target Odyssey is a clinical-stage biotech working on novel mechanistic approache...
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut
Odyssey Therapeutics shares rose 11.1% in its Nasdaq debut on Friday, giving the biopharmaceutical firm a valuation of $899.9 million.
Biotech firm Odyssey raises $279 million in upsized US IPO
Biopharmaceutical company Odyssey Therapeutics has raised $279 million in its upsized U.S. initial public offering, the company said on Thursday.
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoim...
Biotech firm Odyssey targets $810 million in valuation in US IPO
Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in its initial public offering in the United States.